drugset / Trial / NCT00530972

Pilot Study of Patients Chronic Hepatitis C in Co-infected HIV Patients Relapsers After Previous Therapies

NCT00530972

Phase 4 Completed 50 enrolled Hospital Carlos III, Madrid
NaSingle-groupOpen-labelTreatment

Summary

To determine the efficacy and safety of Peginterferón alfa-2a (40 KD) plus Ribavirin in patients who have relapsed or not responded to a previous suboptimal therapy based in Interferon.

Timeline

Start
2006-03
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Peginterferon alfa-2a Protein / enzyme biologic 180 ug
Subject Ribavirin Small molecule 1000 mg
Subject Ribavirin Small molecule 1200 mg